





Therapeutic Development Director, EURORDIS PCWP meeting, 26th November, EMA, London, UK

eurordis.org


Who are we?

An international non-profit, non-governmental umbrella rare disease patients' organisation representing an estimated 30 million individuals in Europe. Our Mission:

- To build a strong pan-European community of patient organisations and people living with rare diseases
- To be their voice at the European level
- To directly or indirectly fight against the impact of rare diseases on their lives



Training programmes at EURORDIS





Objectives of the Summer School

Capacity building programme

Patient engagement all along the life cycle of product development

 Content is continuously adapted in line with evolution in the field of regulation and processes

Format & Content

- 4-days F2F in Barcelona (formal lectures, breakout sessions, mini COMP, mini PDCO, etc.) coupled with online training (quizzes, video recordings, webinars)
- Content not Rare Disease specific, collaboration with ECRIN (participants from other medical fields, medical devices, nutrition, etc)
- Evidence-based medicine, clinical research, clinical trials methodology, ethics, statistics, regulatory principles & processes in the EU, EMA organisation and opportunities for patients, HTA appraisal, pharmacovigilance, etc.




Organisation of four-day programme

- Pre-Summer School preparation
- Four-day programme
 - General organisation

- Days 1 and 2 Clinical trials and Drug development
- Days 3 and 4 EMA overview and committees, HTA, etc.
- Specific organisation
 - Mix of small group sessions and large group formal presentations
 - Problem-based learning model
 - Small group sessions of 10 -12 individuals (maximum) to encourage interactions and exchanges
 - Case-based tutorials





"ExPRESS Yourself!"

Expert Patients and Researchers EURORDIS Summer School

UAB Campus Barcelona, Spain June 1 - 5, 2015




ExPRESS 2015!

30 patient representatives

12 academic researchers

20 different countries



- All rare
- Child with Cystic Fibrosis
- Esophageal Atresia and Tracheo Esophogeal Fistula
- Fabry
- Gaucher
- Juvenile Idiopathic arthritis
- Malattie metaboliche ereditarie
- Melenomas Uveal
- Morbus Osler
- Mucopolysaccaridosis
- Mucopolysaccharidosis type IV
- Myeloma
- Neurofibromatosis
- Neuromuscular and Mitochondrial Pathology
- Niemann Pick Type A B & C
- Ocular Melanoma
- Osteogenesis imperfecta
- Pulmonary arterial hypertension
- Pulmonary hypertension
- Rare and Inherited retina degenerations



ExPRESS 2015!

- This Summer School was co-organised by:
 - COST Action BM2107
 - European Medicines Agency
 - EURORDIS
 - Platforma Malaties Minoritàries

Programme Committee:





Annemieke Aartsma-Rus Monica Ensini Nathalie Goemans Elizabeth Vroom Nathalie Bere Maria Mavris





Josep Torrent-Farnell

eurordis.org



Also thanks to:

Funding from:












- Coordination and local organisation:
 - Nancy Hamilton (EURORDIS)
 - Iolanda Arbiol (Platforma Malaties Minoritàries)
- Our Faculty: Great thanks!! Highly committed people, academics, regulators, industry and expert patients – some of them since the beginning


What is it about? & What is new?

- First Training Programme with Patients and Researchers being trained together
- Blended approach with plenary/formal lectures, small groups sessions, round table discussion and practical exercises ('mock' COMP & SAWP, review of product information, etc.)
- Capacity building Programme → increasing involvement in the R&D processes, Health Technology Assessment, information and access to medicines

Opportunities for Patient involvement along the medicine lifecycle at EMA



Patient involvement all along the product life cycle: interaction with all the stakeholders





Feedback from patients

- Question what did you think about having the researchers with us in the training:
- In discussions with the researchers, I expected more disagreement.
- We never get the chance to exchange with researchers, so it was very special to be able to approach them and realize that they are also normal people!
- In the sessions, it was nice to listen to someone looking at diseases at a totally different perspective.
- It was nice to make personal connections with them as people and see how they relate to our diseases in a different way.
- It was interesting to learn about what they are doing and about what other diseases are doing. The networking opportunity was appreciated.



Feedback from academics

The best thing/what they liked most

- Learned a LOT
- Interaction with patients
- Small group sessions (some said this was where they learned most)
- This is a very unique opportunity to get this type of training
- Participants noted that they have a changed view on the regulatory process and regulators; they understand more why regulation is needed and were pleasantly surprised about how nice and approachable the regulators are
- Patient engagement was made much more tangible, researchers more convinced now that patients can be involved in research every step of the way
- How cultural differences became apparent ... and can be better understood



We are now working on ExPRESS 2016

- Online content accumulated from previous editions of the EURORDIS Summer School such as webcasts and slide presentations as well as webinars, and interactive training modules.
- Even more hands-on/practical approach related to opportunities offered to be engaged into therapeutic development and regulatory processes (Scientific Advice/Protocol Assistance, Early dialogue with HTA bodies, Benefit/Risk assessment at CHMP, Adaptive Pathways, etc.)
- Reinforcement of networking and interactions between patients and researchers - sharing experiences & peer-topeer training



Summer School → Emergence of leadership + Network of alumnis













From 2008 to 2013





